TACSTD2 Specific Neutra™ Antibody Products
Product listTumor-associated calcium signal transducer 2 (TACSTD2), commonly referred to as Trop2, is a transmembrane glycoprotein that belongs to the tumor-associated calcium signal transduction (TACSTD) family. It is encoded by the TACSTD2 gene and is expressed in various human tissues, including the gastrointestinal tract, lung, skin, breast, and pancreas. The TACSTD2 protein is made of an extracellular and transmembrane region, as well as a cytoplasmic tail. It plays a crucial role in cell adhesion, proliferation, and differentiation and has been implicated in cancer progression, making it an attractive target for cancer therapy.
Its Gene ID: 4070, UniProtKB ID: P09758, and OMIM ID: 137290.
TACSTD2 Signaling Pathway
One prominent pathway is the Wnt signaling pathway, where TACSTD2 regulates cell proliferation and differentiation. TACSTD2 interacts with the PI3K/AKT pathway, promoting cell survival and growth. It also influences the MAPK/ERK pathway, facilitating cell migration and invasion. Additionally, TACSTD2 can modulate intracellular calcium signaling, which is crucial in a range of cellular functions. Furthermore, TACSTD2 may interact with other signaling molecules such as EGFR and Src kinases to regulate downstream signaling events. Overall, TACSTD2 is involved in multiple signaling pathways that contribute to its cellular functions and potential roles in cancer development.
Fig.1 Trop2/TACSTD2-mediated signaling pathways.1
TACSTD2-Related Cancer and Other Diseases
TACSTD2 overexpression has been observed in several malignancies, including colorectal, pancreatic, breast, and lung cancers. It is linked to cancer development, metastasis, and poor prognosis. TACSTD2 is also associated with cancer stem cell properties and tumor-initiating abilities. In addition to cancer, TACSTD2 has been implicated in inflammatory bowel disease and autoimmune disorders. Its dysregulation in these conditions contributes to aberrant epithelial cell function, inflammation, and tissue damage. It is involved in the regulation of trophoblast differentiation during pregnancy, and aberrant expression of TACSTD2 has been observed in placental disorders such as preeclampsia. Furthermore, TACSTD2 has been identified as a potential therapeutic target in regenerative medicine due to its role in tissue repair.
Antibodies Targeting TACSTD2
Monoclonal antibodies targeting TACSTD2 have been investigated for their potential diagnostic and therapeutic applications in various cancers. These antibodies aim to inhibit TACSTD2-mediated signaling pathways, thus suppressing tumor growth and metastasis. They may also facilitate targeted drug delivery to cancer cells expressing TACSTD2, enhancing treatment efficacy while minimizing off-target effects. In preclinical models of breast, lung, and pancreatic cancers, anti-TACSTD2 antibodies have shown promising results in reducing tumor burden and improving survival rates. Furthermore, TACSTD2-targeting antibodies have been utilized in diagnostic assays to detect TACSTD2 expression in cancer tissues, which can aid in cancer diagnosis and prognosis.
Fig.2 Structure and mechanism of a Trop2/TACSTD2-directed monoclonal antibody and topoisomerase inhibitor drug conjugate.2
Creative Biolabs offers close to thirty kinds of anti-TACSTD2 antibody products that may be utilized in eight scientific applications. These high-quality, reproducible recombinant antibodies will help you complete your research more efficiently. Additionally, customization of TACSTD2-based neutralizing antibodies is also available for you here.
REFERENCES
- Lenárt, Sára, et al. "Trop2: Jack of all trades, master of none." Cancers 12.11 (2020): 3328. Distributed under Open Access license CC BY 4.0, without modification.
- Koltai, Tomas, and Larry Fliegel. "The Relationship between Trop-2, Chemotherapeutic Drugs, and Chemoresistance." International Journal of Molecular Sciences 25.1 (2023): 87. Distributed under Open Access license CC BY 4.0, without modification.
